A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer

Cisplatin was not associated with a survival advantage over carboplatin when combined with gemcitabine as a first-line treatment of patients with metastatic TNBC, though numerically longer PFS and higher ORR were observed. Differences in safety profiles may help guide individualized treatment decisions.